Resolvin D1‐loaded nanoliposomes promote M2 macrophage polarization and are effective in the treatment of osteoarthritis
Open Access
- 16 December 2021
- journal article
- research article
- Published by Wiley in Bioengineering & Translational Medicine
- Vol. 7 (2) , e10281
Abstract
Current treatments for Osteoarthritis (OA) offer symptomatic relief but do not prevent or halt the disease progression. Chronic low-grade inflammation is considered a significant driver of OA. Specialized proresolution mediators (SPMs) are powerful agents of resolution but have a short in vivo half-life. In this study, we have engineered a Resolvin D1 (RvD1)-loaded nanoliposomal formulation (lipo-RvD1) that targets and resolves the OA-associated inflammation. This formulation creates a depot of the RvD1 molecules that allows the controlled release of the molecule for up to 11 days in vitro. In surgically induced mice model of OA, only controlled-release formulation of lipo-RvD1 was able to treat the progressing cartilage damage when administered a month after the surgery, while the free drug was unable to prevent cartilage damage. We found that lipo-RvD1 functions by damping the proinflammatory activity of synovial macrophages and recruiting a higher number of M2 macrophages at the site of inflammation. Our lipo-RvD1 formulation was able to target and suppress the formation of the osteophytes and showed analgesic effect, thus emphasizing its ability to treat clinical symptoms of OA. Such controlled-release formulation of RvD1 could represent a patient-compliant treatment for OA.Keywords
This publication has 101 references indexed in Scilit:
- Nanoparticles for Improved Local Retention after Intra-Articular Injection into the Knee JointPharmaceutical Research, 2012
- Osteoarthritis: A disease of the joint as an organArthritis & Rheumatism, 2012
- Regulation of osteoarthritis by omega-3 (n-3) polyunsaturated fatty acids in a naturally occurring model of diseaseOsteoarthritis and Cartilage, 2011
- Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actionsNature Medicine, 2010
- OARSI recommendations for the management of hip and knee osteoarthritisOsteoarthritis and Cartilage, 2010
- Resolvin D1 binds human phagocytes with evidence for proresolving receptorsProceedings of the National Academy of Sciences, 2010
- Novel synovial fluid recovery method allows for quantification of a marker of arthritis in miceOsteoarthritis and Cartilage, 2008
- Resolvin E1 regulates interleukin 23, interferon-γ and lipoxin A4 to promote the resolution of allergic airway inflammationNature Immunology, 2008
- Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediatorsThe FASEB Journal, 2008
- Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediatorsNature Reviews Immunology, 2008